Literature DB >> 22617325

MET signaling regulates glioblastoma stem cells.

Kyeung Min Joo1, Juyoun Jin, Eunhee Kim, Kang Ho Kim, Yonghyun Kim, Bong Gu Kang, Youn-Jung Kang, Justin D Lathia, Kwang Ho Cheong, Paul H Song, Hyunggee Kim, Ho Jun Seol, Doo-Sik Kong, Jung-Il Lee, Jeremy N Rich, Jeongwu Lee, Do-Hyun Nam.   

Abstract

Glioblastomas multiforme (GBM) contain highly tumorigenic, self-renewing populations of stem/initiating cells [glioblastoma stem cells (GSC)] that contribute to tumor propagation and treatment resistance. However, our knowledge of the specific signaling pathways that regulate GSCs is limited. The MET tyrosine kinase is known to stimulate the survival, proliferation, and invasion of various cancers including GBM. Here, we identified a distinct fraction of cells expressing a high level of MET in human primary GBM specimens that were preferentially localized in perivascular regions of human GBM biopsy tissues and were found to be highly clonogenic, tumorigenic, and resistant to radiation. Inhibition of MET signaling in GSCs disrupted tumor growth and invasiveness both in vitro and in vivo, suggesting that MET activation is required for GSCs. Together, our findings indicate that MET activation in GBM is a functional requisite for the cancer stem cell phenotype and a promising therapeutic target. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22617325     DOI: 10.1158/0008-5472.CAN-11-3760

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  75 in total

1.  Spatiotemporal genomic architecture informs precision oncology in glioblastoma.

Authors:  Jin-Ku Lee; Jiguang Wang; Jason K Sa; Erik Ladewig; Hae-Ock Lee; In-Hee Lee; Hyun Ju Kang; Daniel S Rosenbloom; Pablo G Camara; Zhaoqi Liu; Patrick van Nieuwenhuizen; Sang Won Jung; Seung Won Choi; Junhyung Kim; Andrew Chen; Kyu-Tae Kim; Sang Shin; Yun Jee Seo; Jin-Mi Oh; Yong Jae Shin; Chul-Kee Park; Doo-Sik Kong; Ho Jun Seol; Andrew Blumberg; Jung-Il Lee; Antonio Iavarone; Woong-Yang Park; Raul Rabadan; Do-Hyun Nam
Journal:  Nat Genet       Date:  2017-03-06       Impact factor: 38.330

2.  Internalized CD44s splice isoform attenuates EGFR degradation by targeting Rab7A.

Authors:  Wei Wang; Honghong Zhang; Sali Liu; Chung Kwon Kim; Yilin Xu; Lisa A Hurley; Ryo Nishikawa; Motoo Nagane; Bo Hu; Alexander H Stegh; Shi-Yuan Cheng; Chonghui Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-17       Impact factor: 11.205

Review 3.  Overcoming therapeutic resistance in glioblastoma: the way forward.

Authors:  Satoru Osuka; Erwin G Van Meir
Journal:  J Clin Invest       Date:  2017-02-01       Impact factor: 14.808

4.  Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3.

Authors:  Ping Mao; Kaushal Joshi; Jianfeng Li; Sung-Hak Kim; Peipei Li; Lucas Santana-Santos; Soumya Luthra; Uma R Chandran; Panayiotis V Benos; Luke Smith; Maode Wang; Bo Hu; Shi-Yuan Cheng; Robert W Sobol; Ichiro Nakano
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

5.  MET signaling promotes DNA repair and radiation resistance in glioblastoma stem-like cells.

Authors:  Pavlina Krasimirova Todorova; Bipasha Mukherjee; Sandeep Burma
Journal:  Ann Transl Med       Date:  2017-02

6.  Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma.

Authors:  Inan Olmez; Ying Zhang; Laryssa Manigat; Mouadh Benamar; Breanna Brenneman; Ichiro Nakano; Jakub Godlewski; Agnieszka Bronisz; Jeongwu Lee; Tarek Abbas; Roger Abounader; Benjamin Purow
Journal:  Cancer Res       Date:  2018-05-29       Impact factor: 12.701

7.  SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation.

Authors:  Fei Liu; Christopher D Cox; Reshmi Chowdhury; Laura Dovek; Huytram Nguyen; Tie Li; Sichen Li; Byram Ozer; Arthur Chou; Nhung Nguyen; Bowen Wei; Joseph Antonios; Horacio Soto; Harley Kornblum; Linda Liau; Robert Prins; P Leia Nghiemphu; William Yong; Timothy Cloughesy; Albert Lai
Journal:  J Neurooncol       Date:  2019-03-05       Impact factor: 4.130

Review 8.  Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma.

Authors:  Gerald C Wallace; Yaenette N Dixon-Mah; W Alex Vandergrift; Swapan K Ray; Catherine P Haar; Amber M Mittendorf; Sunil J Patel; Naren L Banik; Pierre Giglio; Arabinda Das
Journal:  Metab Brain Dis       Date:  2013-04-02       Impact factor: 3.584

9.  Cancer stem cells in glioma: challenges and opportunities.

Authors:  Jialiang Wang; Yufang Ma; Michael K Cooper
Journal:  Transl Cancer Res       Date:  2013-10-01       Impact factor: 1.241

10.  Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells.

Authors:  Kang Ho Kim; Ho Jun Seol; Eun Hee Kim; Jinguen Rheey; Hyun Jin Jin; Yeri Lee; Kyeung Min Joo; Jeongwu Lee; Do-Hyun Nam
Journal:  Neuro Oncol       Date:  2012-12-20       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.